Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 13,608

Document Document Title
WO/2019/072934A1
The present invention relates to compounds of the following formula (I), and to processes for producing and using same to extract one or more metals in a liquid by means of liquid-liquid extraction or by means of solid-liquid extraction ...  
WO/2019/073321A1
The present disclosure relates to effervescent compositions comprising Rifaximin or salt thereof and manufacturing process for the same. The effervescent composition comprises at least one acidic agent and at least one basic agent along ...  
WO/2019/072906A1
The invention relates to compounds of formula (I): wherein the variables are defined in the specification. The invention also relates to a pesticidal mixture comprising a compound of formula (I), and another agrochemically active ingredi...  
WO/2019/073347A1
This invention relates to a crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h ][2,5,11]benzoxadiazacyclo- tetradecine-3-carbonitrile (lorlatinib) free base hydrate...  
WO/2019/074981A1
Heterocyclic compounds as Weel inhibitors are provided. The compounds may find therapeutic agents for the treatment of diseases and may find particular use in oncology.  
WO/2019/072143A1
Disclosed are a 4-aminopyridine derivative, a pharmaceutical composition thereof, a preparation method therefor and a use thereof. The 4-aminopyridine derivative (I) of the present invention, and an isomer, prodrug, stable isotope deriva...  
WO/2019/071355A1
Described are methods and products related to the identification of multiple sclerosis (MS) as a transmissible protein misfolding disorder. Data is presented to support the position that the transmissible protein is an abnormal prion pro...  
WO/2019/075358A1
Described herein are compounds of the formulae (I)-(III) as well as pharmaceutical compositions comprising such compounds and methods for using such compounds/pharmaceutical compositions for treating Alzheimer's disease.  
WO/2019/068511A1
A compound based on 1-Aza-3,7-dioxabicyclo[3.3.0]octane (bicyclic oxazolidine derivative) substituted with 3-(4-isobutyl-2-methylphenyl)propyl, method for their preparation, and their use as pro-fragrances.  
WO/2019/031618A8
The present invention provides a compound represented by formula [I], the compound exhibiting the effect of inhibiting an enzyme that produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I], the structure represe...  
WO/2019/068679A1
The present invention relates to compounds of the formula (1 ) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.  
WO/2019/068507A1
The invention relates to a compound based on 1-Aza-3,7-dioxabicyclo[3.3.0]octane (bicyclic oxazolidine derivative) substituted with 3,7-dimethyl-1,6-nonyldien, method for their preparation, and their use as pro-fragrances.  
WO/2019/068508A1
The invention relates to a compound based on 1-Aza-3,7-dioxabicyclo[3.3.0]octane (bicyclic oxazolidine derivative) substituted with 2-phenylpropyl, method for their preparation, and their use as pro-fragrances.  
WO/2019/070059A1
The present invention provides a commercially applicable method for producing an intermediate of a substituted polycyclic pyridone derivative exhibiting cap-dependent endonuclease inhibitory activity. In the production method shown in th...  
WO/2019/067396A1
Disclosed are compounds of formulas (I) and (V) and compositions thereof useful as inhibitors of ZAP-70 kinase. Also provided are methods of synthesis and methods of use of ZAP-70 inhibitors in treating individuals suffering from organ t...  
WO/2019/065928A1
The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of inflammatory diseases of the central nervous system, or a pharmacologically acceptable salt thereof. Provided is a compound represent...  
WO/2019/061791A1
Disclosed in the invention are a compound and a use thereof. The compound is a compound represented by formula I or a stereoscopic isomer, a racemate, an oxynitride, a hydrate, a metabolite, a pharmaceutically acceptable salt or prodrug ...  
WO/2019/062686A1
Disclosed in the present invention are a compound with cyanobenzene as the core, and an application of the compound in OLED devices. The compound has cyanobenzene as the core and a carbazole cyclic group as a branched chain. The compound...  
WO/2019/064182A1
The disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and method...  
WO/2019/065043A1
Provided are a compound production method capable of producing a benzothiol compound having little coloration, a composition, and a curable composition. The method is for producing a compound represented by formula (1) and comprises reac...  
WO/2019/063708A1
The present invention covers substituted 3-Phenylquinazolin-4(3H)-one compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, phar...  
WO/2019/065791A1
Provided is a compound which has an MAGL inhibitory effect and is expected to be useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Hutchinson's disease, amyotrop...  
WO/2019/032936A8
Provided are lincosamide compounds for the treatment of infectious diseases. The lincosamides described herein are modified at the amino acid (southern) region. The lincosamides may have further modification at the C-1 and C-7 positions ...  
WO/2019/058393A1
Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compo...  
WO/2019/052565A1
Disclosed are a compound as shown in formula (I) as an influenza virus replication inhibitor and a preparation method therefor, a pharmaceutical composition comprising the compound and the use of the compound and pharmaceutical compositi...  
WO/2019/052535A1
The present invention provides a compound for inhibiting and degrading a CDK. Specifically, the present invention provides a compound represented by formula I, definitions of radical groups being described in the specification. The compo...  
WO/2019/053090A1
The present disclosure provides a compound of formula (I): (I); or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treatin...  
WO/2019/055750A1
The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative disease...  
WO/2019/055444A1
The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Y, =, Ar, W, L, and B are as defined as set forth in th...  
WO/2019/054427A1
The present invention addresses the problem of providing a compound having an anti-inflammatory effect, a pharmacologically acceptable salt thereof, etc. The means for solution according to the present invention is a compound represented...  
WO/2019/048808A1
The present invention relates to new polymorphs of dolutegravir sodium and processes for the preparation of the new polymorphs of dolutegravir sodium. The present invention also provides pharmaceutical compositions comprising these new p...  
WO/2019/043407A1
There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists o...  
WO/2019/042470A1
The present invention relates to a compound as a blocker of CD47/SIRPĪ± interaction. In particular, the present invention relates to a compound shown in the following formula I, a pharmaceutical composition comprising the compound of for...  
WO/2019/043610A1
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...  
WO/2019/044844A1
The present invention provides a drug for the prevention and/or treatment of mental illness, the drug including as an active ingredient a Sin3 modulator, in particular the following compound or a pharmacologically acceptable salt thereof...  
WO/2019/038387A1
The invention provides novel pyridylpyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory ...  
WO/2019/038215A1
The invention relates to benzimidazole derivatives of the general formula (I), and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammal...  
WO/2019/037678A1
Provided are a pyrazolo[3,4-d]pyrimidin-3-one derivative as shown in formula (I) or (I') and/or a pharmaceutically acceptable salt thereof, and a composition containing the compound as shown in formula (I) or (I') and/or the pharmaceutic...  
WO/2019/038389A1
The invention provides novel pyridinamine-pyridone and pyrimidinamine- pyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including canc...  
WO/2019/040106A2
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.  
WO/2019/040573A1
The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a ne...  
WO/2019/037761A1
The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activit...  
WO/2019/040550A1
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treatinga neop...  
WO/2019/034153A1
Provided are a pyrimidinyl amino compound having protein kinase inhibitor activity, and a pharmaceutical composition containing said compound; also provided are a use and application of said compound. What is provided is selected from a ...  
WO/2019/034700A1
The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.  
WO/2019/036575A1
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stere...  
WO/2019/034096A1
Fused bicyclic compounds and uses thereof in medicine. In particular, provided are fused bicyclic compounds used as ASK1 active regulator and and use of the compounds in the manufacture of a drug for treating a disease regulated by ASK1....  
WO/2019/032958A1
The present disclosure relates to solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5- f]indol-7-yl)pyrrole-2,5-dione, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof in tre...  
WO/2019/031618A1
The present invention provides a compound represented by formula [I], the compound exhibiting the effect of inhibiting an enzyme that produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I], the structure represe...  
WO/2019/032936A1
Provided are lincosamide compounds for the treatment of infectious diseases. The lincosamides described herein are modified at the amino acid (southern) region. The lincosamides may have further modification at the C-1 and C-7 positions ...  

Matches 1 - 50 out of 13,608